Cited 40 times in
Anti-vascular endothelial growth factor with or without pneumatic displacement for submacular hemorrhage
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 변석호 | - |
dc.contributor.author | 신주연 | - |
dc.date.accessioned | 2016-02-04T11:49:53Z | - |
dc.date.available | 2016-02-04T11:49:53Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 0002-9394 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/141300 | - |
dc.description.abstract | PURPOSE: To compare the treatment outcomes of a combination of pneumatic displacement and intravitreal anti-vascular endothelial growth factor, and anti-vascular endothelial growth factor monotherapy for submacular hemorrhage resulting from exudative age-related macular degeneration. DESIGN: Retrospective, comparative, interventional case series. METHODS: Forty eyes treated with a combination therapy and 42 eyes treated with monotherapy for submacular hemorrhage resulting from exudative age-related macular degeneration with no significant difference in baseline central foveal thickness were compared. Central foveal thickness and best-corrected visual acuity (BCVA) at baseline, 1, 3, and 6 months after initial treatment were measured and compared between the 2 groups after adjustment of baseline central foveal thickness. RESULTS: Central foveal thickness (P < .0001) and BCVA (combination, P < .0001; monotherapy, P = .022) were improved after both treatments. Combination therapy showed more rapid improvement of central foveal thickness (P = .009) and BCVA (P = .007) within 1 month than monotherapy, but there was no difference at 6 months (P = .385 and P = .303, respectively). In eyes with subretinal hemorrhage thicker than 450 μm, visual outcome at 6 months was better in the combination therapy group than in the monotherapy group (P = .021), whereas BCVA showed no significant difference between groups in eyes with subretinal hemorrhage less than 450 μm (P = .930). CONCLUSIONS: Both treatments are useful options for submacular hemorrhage resulting from exudative age-related macular degeneration. Combination therapy may yield a better treatment outcome than monotherapy in eyes with thick subretinal hemorrhage. Nevertheless, the potential for adverse events resulting from pneumatic displacement should be considered. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 904~914 | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF OPHTHALMOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Angiogenesis Inhibitors/therapeutic use* | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized/therapeutic use | - |
dc.subject.MESH | Bevacizumab | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Endotamponade/methods* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorescein Angiography | - |
dc.subject.MESH | Fluorocarbons/administration & dosage | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Intravitreal Injections | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Ranibizumab | - |
dc.subject.MESH | Retinal Hemorrhage/etiology | - |
dc.subject.MESH | Retinal Hemorrhage/physiopathology | - |
dc.subject.MESH | Retinal Hemorrhage/therapy* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Sulfur Hexafluoride/administration & dosage | - |
dc.subject.MESH | Tomography, Optical Coherence | - |
dc.subject.MESH | Vascular Endothelial Growth Factor A/antagonists & inhibitors* | - |
dc.subject.MESH | Visual Acuity/physiology | - |
dc.subject.MESH | Wet Macular Degeneration/complications | - |
dc.subject.MESH | Wet Macular Degeneration/drug therapy* | - |
dc.subject.MESH | Wet Macular Degeneration/physiopathology | - |
dc.title | Anti-vascular endothelial growth factor with or without pneumatic displacement for submacular hemorrhage | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Ophthalmology (안과학) | - |
dc.contributor.googleauthor | Joo Youn Shin | - |
dc.contributor.googleauthor | Ji-min Lee | - |
dc.contributor.googleauthor | Suk Ho Byeon | - |
dc.identifier.doi | 10.1016/j.ajo.2015.01.024 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01849 | - |
dc.contributor.localId | A02154 | - |
dc.relation.journalcode | J00097 | - |
dc.identifier.eissn | 1879-1891 | - |
dc.identifier.pmid | 25637179 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0002939415000537 | - |
dc.contributor.alternativeName | Byeon, Suk Ho | - |
dc.contributor.alternativeName | Shin, Joo Youn | - |
dc.contributor.affiliatedAuthor | Byeon, Suk Ho | - |
dc.contributor.affiliatedAuthor | Shin, Joo Youn | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 159 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 904 | - |
dc.citation.endPage | 914 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF OPHTHALMOLOGY, Vol.159(5) : 904-914, 2015 | - |
dc.identifier.rimsid | 31466 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.